Selenium
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
333 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | 5 | 3 | 7 | 16 |
| Neoplasms | D009369 | — | C80 | 3 | 1 | 2 | 3 | 4 | 12 |
| Thyroid diseases | D013959 | — | E00-E07 | — | 3 | 3 | 1 | 5 | 10 |
| Autoimmune thyroiditis | D013967 | EFO_0006812 | E06.3 | — | 2 | — | 1 | 6 | 9 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | 1 | 6 | 8 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | 1 | — | 1 | 5 | 7 |
| Syndrome | D013577 | — | — | — | 1 | — | 2 | 4 | 7 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 2 | 2 | 1 | 2 | 7 |
| Thyroiditis | D013966 | — | E06 | — | — | — | 1 | 5 | 6 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | 1 | 1 | 4 | 6 |
Show 47 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 5 | 7 | 4 | — | 2 | 17 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | 3 | — | 9 | 13 |
| Covid-19 | D000086382 | — | U07.1 | — | 3 | 2 | — | 5 | 9 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 2 | — | 6 | 9 |
| Healthy volunteers/patients | — | — | — | — | 1 | 1 | — | 5 | 7 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | 3 | — | 1 | 6 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 4 | — | 1 | 5 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 1 | — | 3 | 5 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | 2 | 3 | — | 2 | 5 |
| Precancerous conditions | D011230 | — | — | — | — | 4 | — | — | 4 |
Show 59 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 4 | 5 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 1 | — | — | — | 2 |
| Thyrotoxicosis | D013971 | — | E05 | — | 1 | — | — | 1 | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | 1 | 2 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
| Adenocarcinoma of lung | D000077192 | — | — | — | 1 | — | — | — | 1 |
| Bronchiolo-alveolar adenocarcinoma | D002282 | — | — | — | 1 | — | — | — | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 1 | — | — | — | 1 |
| Male urogenital diseases | D052801 | — | — | — | 1 | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | 2 | 3 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | — | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | — | 1 |
| Lymphangioma | D008202 | — | D18.1 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iron deficiencies | D000090463 | — | E61.1 | — | — | — | — | 5 | 5 |
| Dandruff | D063807 | — | L21.0 | — | — | — | — | 5 | 5 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 3 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
| Diarrhea | D003967 | — | R19.7 | — | — | — | — | 3 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 3 | 3 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 3 | 3 |
| Hyperthyroidism | D006980 | — | E05.9 | — | — | — | — | 3 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 3 | 3 |
| Fibrosis | D005355 | — | — | — | — | — | — | 3 | 3 |
Show 126 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
+
Selenium
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
804 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use